✦ LIBER ✦

A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the north central cancer treatment group

✍ Scribed by Dean H. Gesme Jr.; James R. Jett; Dennis D. Schreffler; John Q. Su; James A. Mailliard; John F. Foley; James E. Krook; Andrew W. Maksymiuk; Alan K. Hatfield; Larry P. Ebbert; Delano M. Pfeifle; Roscoe F. Morton; Loren K. Tschetter; Paul I. Schaefer

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 376 KB
Volume: 71
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930501)71:9<2723::aid-cncr2820710906>3.0.co;2-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of carboplatin in untre

A phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer

✍ Cinta Pallares; Miguel Angel Izquierdo; Alfredo Paredes; Alberto Fernandez Sagar 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB 👁 1 views

A north central cancer treatment group P

A north central cancer treatment group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma

✍ Henry C. Pitot; James A. Knost; Michelle R. Mahoney; John Kugler; James E. Krook 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

A phase III trial of 5-fluorouracil and

A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study

✍ Michael J. O'Connell 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB 👁 2 views

The Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) conducted a randomized clinical trial comparing five different combination chemotherapeutic regimens to single-agent 5-fluorouracil (5-FU), given by intravenous bolus technique (500 mg/m2 for 5 days) as a control, in the treatment

Phase II trial of a 75-mg/m2 dose of doc

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

✍ Vincent A. Miller; James R. Rigas; Prudence A. Francis; Stefan C. Grant; Katheri 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 493 KB 👁 1 views

## Background. A prior Phase I1 study of a 100-mg/m2 dose of docetaxel conducted at the Memorial Sloan-Kettering Cancer Center (New York, NY) demonstrated a 38% response rate with grade 3 or 4 neutropenia in 76% of the patients and a grade 2 or greater rash or infusionrelated reaction in 41% and 3

Carboplatin, methotrexate, and vinblasti

Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial

✍ Francesco Boccardo; Maurizio Pace; Domenico Guarneri; Luciano Canobbio; Antonio 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 395 KB 👁 1 views

Increasing dose intensity of cisplatin-e

Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma : A Phase III randomized trial of the Spanish lung cancer group

✍ Albert Font; Alfredo J. Moyano; Jose M. Puerto; Alejandro Tres; Carlos Garcia-Gi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

## Background: The authors designed this randomized, controlled trial to assess whether dose intensification of a cisplatin-etoposide combination (pe), achieved by shortening the interval between chemotherapy cycles, would improve response rate and survival. the maximum tolerated dose of pe was adm